

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
 (Use several sheets if necessary)

Sheet 1 of 7



ATTORNEY DOCKET NO.

6102-000042/US/NP

SERIAL No.

10/522,697

APPLICANT

Zambrana, J., et al.

FILING DATE

27 January 2005

GROUP

1626

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1	/JN/	US 5137901 A	08/11/1992	United States	C07D 417/00	
2	/JN/	US 6919360 B2	07/19/2005	United States	C07D 417/12	

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
3	/JN/	EP 0352613 B1	04/20/1994	Europe	C07D 417/12	X	
4	/JN/	ES 2052829 T3	07/16/1994	Spain	C079D 417/12	X	
5	/JN/	WO 199606846 A1	03/07/1996	PCT	C07D 487/04	X (abstract only)	
6	/JN/	ES 2082727 A1	03/16/1996	Spain	C07D 487/04		X
7	/JN/	ES 2094690 A1	01/16/1997	Spain	C07D 207/452	X (abstract only)	
8	/JN/	WO 199735860 A1	10/02/1997	PCT	C07D 154/14	X (abstract only)	
9	/JN/	ES 2109190 A1	01/01/1998	Spain	C07D 451/04		X
10	/JN/	WO 199915527 A1	04/01/1999	PCT	C07D 487/04	X (abstract only)	
11	/JN/	ES 2129370 A1	06/01/1999	Spain	C07D 487/04		X
12	/JN/	WO 199929687 A1	06/17/1999	PCT	C07D 405/14		

Examiner: /Jason Nolan/

Date Considered: 11/05/2007

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 2 of 7	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000042/US/NP	10/522,697
	APPLICANT	
	Zambrana, J., <i>et al.</i>	
	FILING DATE	GROUP
	27 January 2005	1626

FOREIGN PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
13	/JN/	ES 2154605 A1	04/01/2001	Spain	C07D 451/04	X (abstract only)	
14	/JN/	WO 2003029250 A1	04/10/2003	PCT	C07D 417/12	X	
15	/JN/	ES 2199086 A1	02/01/2004	Spain	C07D 487/04		X
16	/JN/	WO 2004014915 A1	02/19/2004	PCT	C07D 487/04	X (abstract only)	
17	/JN/	ES 2238015 A1	08/01/2005	Spain	C07D 487/04	X	
18	/JN/	WO 2005075480 A1	08/18/2005	PCT	C07D 487/04		
19	/JN/	EP 1674103 A1	06/28/2006	Europe	C07D 487/04		
20	/JN/	WO 2006069993 A1	07/06/2006	PCT	C07D 487/04		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
21	/JN/	Ambrossio, E. et al., [3H]prazosin binding to central nervous system regions of male and female rats, NEUROSCI. LETT. 49(1-2):193-197 (1984)
22	/JN/	Titeler, M. et al., Selectivity of serotonergic drugs for multiple brain serotonin receptors: Role of [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB), A 5-HT ₂ agonist radioligand, BIOCHEM. PHARMACOL. 36(19):3265-3271 (1987)
23	/JN/	Wong, D.T. et al., Specific [3H]LY278584 binding to 5-HT ₂ recognition sites in rat cerebral cortex, EUR. J. PHARMACOL. 166(1):107-110 (1989)
24	/JN/	Clark, R.D. et al., 1,90ALKano-Bridged 2,3,4,5-Tetrahydro-1H-3-benzazepines with affinity for the α_2 -adrenoceptor and the 5-HT _{1a} receptor, J. MED. CHEM. 33(2):633-641 (1990)

Examiner: /Jason Nolan/	Date Considered: 11/05/2007
-------------------------	-----------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 3 of 7	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000042/US/NP	10/522,697
	APPLICANT	
	Zambrana, J., <i>et al.</i>	
	FILING DATE	GROUP
	27 January 2005	1626

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
25	/JN/	Grossman, C.J. et al., <i>Development of a radioligand binding assay for 5-HT₄ receptors in guinea-pig and rat brain</i> , BR. J. PHARMACOL. 109:618-624 (1993)
26	/JN/	De Vry, J., <i>5-HT_{1A} receptor agonists: recent developments and controversial issues</i> , PSYCHOPHARMACOLOGY 121(1):1-16 (1995)
27	/JN/	Koh, J.Y. et al., <i>Potentiated necrosis of cultured cortical neurons by neurotrophins</i> , SCIENCE 268(5210):573-575 (1995)
28	/JN/	Koroshetz, W.J. and Moskowitz, M.A., <i>Emerging treatments for stroke in humans</i> , TRENDS PHARMACOL. SCI. 17(6):227-33 (1996)
29	/JN/	Lopez-Rodriguez, M.L. et al., <i>Novel benzimidazole-4-carboxylic acid derivatives as potent and selective 5-HT₃ receptor ligands</i> , BIOORG. MED. CHEM. LETT. 6(11): 1195-1198 (1996)
30	/JN/	Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxyphenyl)piperazin-1-yl]methyl]-1,3-dioxoperhydroimidazo[1,5-α]pyridine: a selective 5-HT_{1A} receptor agonist</i> , J. MED. CHEM. 39(22):4439-4450 (1996)
31	/JN/	Lopez-Rodriguez, M.L. et al., <i>2-[4-(o-Methoxyphenyl)piperazin-1-ylmethyl]-1,3-dioxoperhydroimidazo[1,5-α]pyridine as a new selective 5-HT_{1A} receptor ligand</i> , BIOORG. MED. CHEM. LETT. 6(6):689-694 (1996)
32	/JN/	Matsuyama, S. et al., <i>Regulation of glutamate release via NMDA and 5-HT_{1A} receptors in guinea pig dentate gyrus</i> , BRAIN RES. 728(2):175-180 (1996)
33	/JN/	Lopez-Rodriguez, M.L. et al., <i>Comparative receptor mapping of serotonergic 5-HT₃ and 5-HT₄ binding sites</i> , J. COMPUT.-AIDED MOL. DES. 11(6):589-599 (1997)
34	/JN/	Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of arylpiperazines. 2. Three-dimensional quantitative structure-activity relationships of hydantoin-phenylpiperazine derivatives with affinity for 5-HT_{1A} and α1 receptors. A comparison of CoMFA models</i> , J. MED. CHEM. 40(11):1648-1656 (1997)
35	/JN/	Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of arylpiperazines. 3.1 2-[omega-(4-aryl piperazin-1-yl)alkyl]perhydropyrrolo-[1,2-c]imidazoles and -perhydroimidazo[1,5-α]pyridines: study of the influence of the terminal amide fragment on 5-HT_{1A} affinity/selectivity</i> , J. MED. CHEM. 40(16):2653-2656 (1997)
36	/JN/	Aguirre, N. et al., <i>MDMA ('Ecstasy') enhances 5-HT_{1A} receptor density and 8-OH-DPAT-induced hypothermia: Blockade by drugs preventing 5-hydroxytryptamine depletion</i> , EUR. J. PHARMACOL. 346(2-3):181-188 (1998)

Examiner: /Jason Nolan/	Date Considered: 11/05/2007
-------------------------	-----------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 4 of 7	ATTORNEY DOCKET No.	SERIAL No.
	6102-000042/US/NP	10/522,697
	APPLICANT	
	Zambrana, J., <i>et al.</i>	
	FILING DATE	GROUP
	27 January 2005	1626

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
37	/JN/	Beneytez, M.E. et al., <i>Preclinical pharmacology of B-20991, a 5-HT_{1A} receptor agonist with anxiolytic activity</i> , EUR. J. PHARMACOL. 344:127-135(1998)
38	/JN/	Lopez-Rodriguez, M.L. et al., <i>1-[ω-(4-Arylpiperazin-1-yl)alkyl]-3-diphenylmethylene-2,5-pyrrolidinediones as 5-HT_{1A} receptor ligands: Study of the steric requirements of the terminal amide fragment on 5-HT_{1A} affinity/selectivity</i> , BIOORG. MED. CHEM. LETT. 8:581-586(1998)
39	/JN/	Nonaka, S. et al., <i>Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx</i> , PROC. NAT'L. ACAD. SCI. USA 95(5):2642-2647 (1998)
40	/JN/	Suchanek, B. et al., <i>The 5-HT_{1A} receptor agonist BAY x 3702 prevents staurosporine-induced apoptosis</i> , EUR. J. PHARMACOL. 355(1):95-101 (1998)
41	/JN/	Ahlemeyer B. et al., <i>The 5-HT_{1A} receptor agonist Bay x 3702 inhibits apoptosis induced by serum deprivation in cultured neurons</i> , EUR. J. PHARMACOL. 370(2):211-216 (1999)
42	/JN/	Justicia, C. and Planas, A.M., <i>Transforming growth factor-α acting at the epidermal growth factor receptor reduces infarct volume after permanent middle cerebral artery occlusion in rats</i> , J. CEREB. BLOOD FLOW METAB. 19(2):128-132 (1999)
43	/JN/	Lopez-Rodriguez, M.L. et al., <i>Benzimidazole derivatives. 1. Synthesis and structure-activity relationships of new benzimidazole-4-carboxamides and carboxylates as potent and selective 5-HT₁ receptor antagonists</i> , BIOORG. MED. CHEM. 7:2271-2281 (1999)
44	/JN/	Lopez-Rodriguez, M.L. et al., <i>Benzimidazole derivatives. 2. Synthesis and structure-activity relationships of new azabicyclic benzimidazole-4-carboxylic acid derivatives with affinity for serotonergic 5-HT₃ receptors</i> , J. MED. CHEM. 42:5020-5028 (1999)
45	/JN/	Lopez-Rodriguez, M.L. et al., <i>Design and synthesis of 2-[4-[4-(m-(ethylsulfonamido)phenyl)piperazin-1-yl]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole (EF-7412) using neural networks. A selective derivative with mixed 5-HT_{1A}/D₂ antagonist properties</i> , BIOORG. MED. CHEM. LETT. 9:1679-1682 (1999)
46	/JN/	Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene) - 2,5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2,5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT_{1A} affinity/selectivity</i> , J. MED. CHEM. 42(1):36-49 (1999)

Examiner:	/Jason Nolan/	Date Considered:	11/05/2007
-----------	---------------	------------------	------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 5 of 7	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000042/US/NP	10/522,697
	APPLICANT	
	Zambrana, J., <i>et al.</i>	
	FILING DATE	GROUP
	27 January 2005	1626

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
47	/JN/	Lopez-Rodriguez, M.L. et al., <i>Synthesis of new (benzimidazolyl)piperazines with affinity for the 5-HT_{1A} receptor via Pd(0) amination of bromobenzimidazoles</i> , BIOORG. MED. CHEM. LETT. 9:2339-2342, 1999
48	/JN/	Galter, D. et al., <i>Sequential activation of the 5-HT_{1A} serotonin receptor and TrkB induces the serotonergic neuronal phenotype</i> , MOL. CELL. NEUROSCI. 15(5):446-455 (2000)
49	/JN/	Lopez-Rodriguez, M.L. et al., <i>First pharmacophoric hypothesis for 5-HT₇ antagonism</i> , BIOORG. MED. CHEM. LETT. 10:1097-1100 (2000)
50	/JN/	Lopez-Rodriguez, M.L. et al., <i>Pd(0) Amination of benzimidazoles as an efficient method towards new (benzimidazolyl)piperazines with high affinity for the 5-HT_{1A} receptor</i> , TETRAHEDRON 56:3245-3253 (2000)
51	/JN/	Schaper, C. et al., <i>Stimulation of 5-HT_{1A} receptors reduces apoptosis after transient forebrain ischemia in the rat</i> , BRAIN RES. 883(1): 41-50 (2000)
52	/JN/	Torup, L. et al., <i>Neuroprotective effect of 8-OH-DPAT in global cerebral ischemia assessed by stereological cell counting</i> , EUR. J. PHARMACOL. 395(2):137-141 (2000)
53	/JN/	Kline, A.E. et al., <i>The selective 5-HT_{1A} receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats</i> , NEUROSCIENCE 106(3) 547-555 (2001)
54	/JN/	Lopez-Rodriguez, M.L. et al., <i>Computational model of the complex between GR113808 and the 5-HT₄ receptor guided by site-directed mutagenesis and the crystal structure of rhodopsin</i> , J. COMPUT.-AIDED. MOL. DES. 15: 1025-1033 (2001)
55	/JN/	Lopez-Rodriguez, M.L. et al., <i>Study of the bioactive conformation of novel 5-HT₄ receptor ligands: influence of an intramolecular hydrogen bond</i> , TETRAHEDRON 57:6745-6749 (2001)
56	/JN/	Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of arylpiperazines. 5. Study of the physicochemical influence of the pharmacophore on 5-HT(1a)/alpha(1)-adrenergic receptor affinity: synthesis of a new derivative with mixed 5-HT(1a)/d(2) antagonist properties</i> , J. MED. CHEM. 44(2):186-197 (2001)
57	/JN/	Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of arylpiperazines. 6. Study of the 5-HT(1a)/alpha(1)-adrenergic receptor affinity by classical hansch analysis, artificial neural networks, and computational simulation of ligand recognition</i> , J. MED. CHEM. 44(2):198-207 (2001)

Examiner:	/Jason Nolan/	Date Considered:	11/05/2007
-----------	---------------	------------------	------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 6 of 7	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000042/US/NP	10/522,697
	APPLICANT	
	Zambrana, J., <i>et al.</i>	
	FILING DATE	GROUP
	27 January 2005	1626

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
58	/JN/	Lopez-Rodriguez, M.L. et al., <i>3D-QSAR/CoMFA and recognition models of benzimidazole derivatives at the 5-HT₄ receptor</i> BIOORG. MED. CHEM. LETT. 11:2807-2811 (2001)
59	/JN/	Mauler, F., et al., <i>Inhibition of evoked glutamate release by the neuroprotective 5-HT_{1A} receptor agonist BAY x 3702 in vitro and in vivo</i> , BRAIN RES. 888(1):150-157 (2001)
60	/JN/	Caicoya, A.G. et al., <i>Biochemical, electrophysiological and neurohormonal studies with B-20991, a selective 5-HT_{1A} receptor agonist</i> , PHARMACOLOGY 62: 234-242 (2001)
61	/JN/	Lopez-Rodriguez, M.L. et al., <i>Arylpiperazine derivatives acting at 5-HT_{1A} receptors</i> , CURR. MED. CHEM. 9:443-469 (2002)
62	/JN/	Lopez-Rodriguez, M.L. et al., <i>Benzimidazole derivatives. 3. 3D-QSAR/CoMFA model and computational simulation for the recognition 5-HT₄ receptor antagonists</i> , J. MED. CHEM. 45: 4806-4815 (2002)
63	/JN/	Lopez-Rodriguez, M.L. et al., <i>Design, synthesis and pharmacological evaluation of 5-hydroxytryptamine_{1A} receptor ligands to explore the three-dimensional structure of the receptor</i> , MOL. PHARMACOL. 62:15-21 (2002)
64	/JN/	Lopez-Rodriguez, M.L. et al., <i>5-HT₄ receptor antagonists: structure-affinity relationships and ligand-receptor interactions</i> , CURR. TOPICS MED. CHEM. 2:625-641 (2002)
65	/JN/	Lopez-Rodriguez, M.L. et al., <i>Benzimidazole derivatives. 4. The recognition of the voluminous substituent attached to the basic amino group of 5-HT₄ receptor antagonists</i> , J. COMPUT.-AIDED MOL. DES. 17:515-524 (2003)
66	/JN/	Lopez-Rodriguez, M.L. et al., <i>Design and synthesis of new benzimidazole-arylpiperazine derivatives acting as mixed 5-HT_{1A}/5-HT₃ ligands</i> , BIOORG. MED. CHEM. LETT. 13:3177-3180 (2003)
67	/JN/	Lopez-Rodriguez, M.L. et al., <i>Design and synthesis of S-(-)-2-[[4-(naphth-1-yl)piperazin-1-yl]methyl]-1,4-dioxoperhydropyrrolo[1,2-a]pyrazine (CSP-2503) using computational simulation. A 5-HT_{1A} receptor agonist</i> , BIOORG. MED. CHEM. LETT. 13(8):1429-1432 (2003)
68	/JN/	Lopez-Rodriguez, M.L. et al., <i>Optimization of the pharmacophore model for 5-HT₇ receptor antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives</i> , J. MED. CHEM. 46:5638-5650 (2003)
69	/JN/	Pascual D. et al., <i>New benzimidazole derivatives: selective and orally active 5-HT₃ receptor antagonists</i> , EUR. J. PHARMACOL. 462:99-107 (2003)

Examiner: /Jason Nolan/	Date Considered: 11/05/2007
-------------------------	-----------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 7 of 7	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000042/US/NP	10/522,697
	APPLICANT	
	Zambrana, J., <i>et al.</i>	
	FILING DATE	GROUP
	27 January 2005	1626

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
70	/JN/	Lopez-Rodriguez, M.L. et al., <i>Benzimidazole derivatives. 5. Design and synthesis of new benzimidazole-arylpiperazine derivatives acting as mixed 5-HT_{1A}/5-HT₃ ligands</i> , BIOORG. MED. CHEM. 12:5181-5191 (2004)
71	/JN/	Lopez-Rodriguez, M.L. et al., <i>Serotonin 5-HT₇ receptor antagonists</i> , CURR. MED. CHEM.-CNSA 4:203-214 (2004)
72	/JN/	Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of arylpiperazines. Part 7: Study of the influence of lipophilic factors at the terminal amide fragment on 5-HT_{1A} affinity/selectivity</i> , BIOORG. MED. CHEM. 12(6):1551-1557 (2004)
73	/JN/	Delgado, M. et al., <i>Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT_{1A}, 5-HT_{2A} and 5-HT₃ receptors</i> , EUR. J. PHARMACOL. 511:9-19 (2005)
74	/JN/	Lopez-Rodriguez, M.L. et al., <i>A three-dimensional pharmacophore model for 5-hydroxytryptamine₆ (5-HT₆) receptor antagonists</i> , J. MED. CHEM. 48:4216-4219 (2005)
75	/JN/	Lopez-Rodriguez, M.L. et al., <i>Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT_{1A}R agonists with selectivity over alpha1-adrenoceptors</i> , J. MED. CHEM. 48(7):2548-2558 (2005)

Examiner:	/Jason Nolan/	Date Considered:	11/05/2007
-----------	---------------	------------------	------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.